Desmoid fibromatosis (DF) is a rare, unpredictable disease with no established, evidence-based treatments. Individual management is based on consensus algorithms. This study aimed to examine the specific health-related quality of life challenges faced by DF patients, current experiences and expectations of care.
Twenty-seven DF patients were purposively sampled from The Royal Marsden Hospital. Two focus groups and 13 interviews (males 12, females 15; mean age at study 39.5 years) explored health-related quality of life issues and experiences of healthcare. Thematic content was analysed.
Discussions revealed four key themes (diagnostic pathway; treatment pathway; living with DF; supportive care). Diagnostic delay resulted from lack of recognition by patients and healthcare professionals. Some patients received an initial diagnosis of cancer, causing significant distress. Treatment decisions were challenging, and patients experienced uncertainty among clinicians about optimal therapies. Side-effects of treatment were severe, including fatigue, nausea, anorexia, low libido and depression. Pain was the most debilitating symptom and dependency on painkillers was a significant concern. Functional limitation and restricted mobility frequently affected daily activities. Patients experienced difficulty accomplishing their role in society; relationship problems, caring for children, employment and financial difficulties. Social isolation and lack of understanding were common. The psychological impact of this “life-changing and life-long” condition was profound. All patients requested knowledgeable healthcare professionals, more information, continuity of care and peer support.
DF patients face complex physical, psychological and practical challenges. Comprehensive care services are needed. Increasing awareness may help to improve diagnostic pathways and overall patient experience.
WHO Classification of Tumours, Volume 5 IARC WHO Classification of Tumours, No 5 Fletcher, C. D.M., Bridge, J.A., Hogendoorn, P., Mertens, F Desmoid-type fibromatosis. Lyon: IARC Press, 2013
Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A, Desmoid Working Group, Bauer S, Blay JY, van Coevorden F, Dileo P, Dürr HR, Fiore M, Grünwald V, Jones R, Judson I, Kettelhack C, Kopeckova K, Lazar A, Lindner LH, Martin-Broto J, Rutkowski P, Stacchiotti S, Stoeckle E, Valverde C, Verhoef K, Wardelmann E, Wartenberg M (2017) An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 28:2399–2408 CrossRefPubMed
Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, van der Graaf W, Gronchi A, Desmoid Working Group (2015) Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer 51:127–136 CrossRefPubMed
Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, Bonvalot S, Stoeckle E, Guillou L, le Cesne A, Oberlin O, Brouste V, Coindre JM (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553–3558 CrossRefPubMed
Kummar S, O'Sullivan Coyne G, Do KT, et al. (2017) Clinical Activity of the gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35(14):1561–1569
Villalobos VM, Hall F, Jimeno A, et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol https://doi.org/10.1245/s10434-017-6082-1
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376 CrossRefPubMed
Fayers P, Aaronson NK, Bjordal K, Group. ObotEQoL. The EORTC QLQ-C30 scoring manual. Brussels: EORTC,2001
Braun VCV (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77–101 CrossRef
Joffe H YL (2004) Content and thematic analysis. Methods Clin Health Psychol; 56
Elliott E, Zurynski Y (2015) Rare diseases are a ‘common’ problem for clinicians. Aust Fam Physician 44:630–633 PubMed
Risberg T, Sorbye SW, Norum J, Wist EA (1996) Diagnostic delay causes more psychological distress in female than in male cancer patients. Anticancer Res 16:995–999 PubMed
Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P (2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German interdisciplinary sarcoma group (GISG). Eur J Cancer 76:60–67 CrossRefPubMed
Gordon DB, Dahl JL, Miaskowski C, McCarberg B, Todd KH, Paice JA, Lipman AG, Bookbinder M, Sanders SH, Turk DC, Carr DB (2005) American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 165:1574–1580 CrossRefPubMed
- Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care?
Dirk C. Strauss
Andy J. Hayes
Winan van Houdt
Robin L. Jones
Winette T. A. van der Graaf
- Springer Berlin Heidelberg
Supportive Care in Cancer
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
Neu im Fachgebiet Onkologie
Mail Icon II